Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy | Abstract

Asploro Journal of Biomedical and Clinical Case Reports

Asploro Journal of Biomedical and Clinical Case Reports [ISSN: 2582-0370]

ISSN: 2582-0370

Article Type: Case Report

DOI: 10.36502/2021/ASJBCCR.6233

Asp Biomed Clin Case Rep. 2021 Apr 06;4(1):77-83

Hiroshi Bando1,2*, Yoshinobu Kato2, Yoshikane Kato2, Sayuri Matsuzaki2, Shinnichi Waka2, Katsunori Ogura2
1Tokushima University/Medical Research, Tokushima, Japan
2Kanaiso Hospital, Komatsushima, Tokushima, Japan

Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University/Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 19 February 2021; Accepted date: 29 March 2021; Published date: 06 April 2021

Citation: Bando H, Kato Y, Kato Y, Matsuzaki S, Waka S, Ogura K. Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy. Asp Biomed Clin Case Rep. 2021 Apr 06;4(1):77-83.

Copyright © 2021 Bando H, Kato Y, Kato Y, Matsuzaki S, Waka S, Ogura K. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Xultophy, Degludec and Liraglutide, Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist, Dual Action of Liraglutide and Insulin Degludec, European Xultophy Treatment Retrospective Audit

Abbreviations: IDegLira: Degludec and Liraglutide; GLP-1RA: Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist; DUAL: Dual Action of Liraglutide and Insulin Degludec; EXTRA: European Xultophy Treatment Retrospective Audit

Abstract

The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was improved satisfactory, suggesting the dual synergistic effects.

Facebooktwitterlinkedininstagramflickrfoursquaremail

asploro

Asploro Open Access Publications Limited